Questions About Cancer? 1-800-4-CANCER
  • Posted: 01/06/2014
NCI Cancer Center News

Recurrent ovarian cancers respond to cancer vaccine after “reprogramming” with decitabine

Treatment with the drug decitabine prior to administration of chemotherapy and a cancer vaccine yielded clinical benefit for women with recurrent ovarian cancer, suggesting that this combinatorial chemoimmunotherapy may provide a new treatment option for patients with this disease, according to a Roswell Park Cancer Institute study published in Cancer Immunology Research, a journal of the American Association for Cancer Research.

Click here to read the full press release.

###

NCI Comprehensive Cancer Center logoAmong the research institutions NCI funds across the United States, it currently designates 68 as Cancer Centers. Largely based in research universities, these facilities are home to many of the NCI-supported scientists who conduct a wide range of intense, laboratory research into cancer’s origins and development. The Cancer Centers Program also focuses on trans-disciplinary research, including population science and clinical research. The centers’ research results are often at the forefront of studies in the cancer field.